EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Eugenol as a Novel Neuroblastoma Therapeutic Identified by an Online Prognostic Assessment Platform

Ruizong Wang, Chunxi Long

Frontiers in Bioscience-Landmark · 2025

DOI: 10.31083/fbl46406 ↗

At a glance

Journal article in Frontiers in Bioscience-Landmark, 2025. Written by Ruizong Wang and 1 co-authors. Institution: Department of Neurosurgery Children's Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents' Healt…. Major MEDLINE topics: Neuroblastoma, Eugenol. 41 references. The full text is freely available (open access, CC BY 4.0). Funded by: Children's Hospital of Chongqing Medical University Nursing Department-Level Research Project, Children’s Hospital of Chongqing Medical University Nursing Department-Level Research Project.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

High-risk neuroblastoma (NB) remains a therapeutic challenge with a poor prognosis, necessitating the identification of novel prognostic biomarkers and effective therapeutics.

Methods

We analyzed transcriptomic datasets from public repositories using weighted gene co-expression network analysis to identify gene modules associated with prognosis. Consensus clustering stratified patients into distinct subgroups. Differential expression analysis, integrated with 80 machine learning algorithm combinations, prioritized hub genes to construct a risk-scoring model, which was implemented via an online platform. We then screened the new drug eugenol using the proximity algorithm and explored its feasibility through in vitro trials.

Results

Consensus clustering based on prognosis-associated modules revealed two patient subgroups with significantly different survival differences (p < 0.001). A set of six hub genes (chromosome 21 open reading frame 58 (C21orf58), cannabinoid receptor 1 (CNR1), laminin alpha 4 (LAMA4), leptin receptor (LEPR), solute carrier family 25 member 10 (SLC25A10), and telomerase reverse transcriptase (TERT)) was identified and used to build a risk-scoring model, accessible at online platform. Leveraging this model, we identified eugenol as a potential therapeutic candidate. Transcriptome analysis showed that eugenol selectively targeted high-risk NB cell populations predicted by the model. Preliminary in vitro experiments investigating its mechanism of action indicated that eugenol primarily functions by inhibiting the MYC-cyclin D1 (CCND1) axis.

Conclusions

This study establishes an integrated precision medicine framework for NB, identifying a new high-risk group and suggesting eugenol as a promising therapeutic candidate for this group, potentially acting through MYC-CCND1 axis suppression.

Subjects

MeSH terms (MEDLINE)

NeuroblastomaEugenolHumansPrognosisGene Expression Regulation, NeoplasticGene Expression ProfilingCell Line, TumorBiomarkers, TumorTranscriptomeGene Regulatory NetworksMachine Learning

Author keywords

eugenolmachine learningneuroblastomatranscriptome

Substances

EugenolBiomarkers, Tumor

Authors and institutions

  • Department of Neurosurgery Children's Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents' Health and Diseases, Ministry of Education Key Laboratory of Child Developm…

Funding

  • Children's Hospital of Chongqing Medical University Nursing Department-Level Research Project
  • Children’s Hospital of Chongqing Medical University Nursing Department-Level Research Project

Cite

APA

Wang, R., & Long, C. (2025). Eugenol as a Novel Neuroblastoma Therapeutic Identified by an Online Prognostic Assessment Platform. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl46406

Vancouver

Wang R, Long C. Eugenol as a Novel Neuroblastoma Therapeutic Identified by an Online Prognostic Assessment Platform. Frontiers in Bioscience-Landmark. 2025. doi:10.31083/fbl46406

BibTeX
@article{Wang2025,
  author = {Wang, Ruizong and Long, Chunxi},
  title = {Eugenol as a Novel Neuroblastoma Therapeutic Identified by an Online Prognostic Assessment Platform},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2025},
  doi = {10.31083/fbl46406}
}
Start for free →